Biotech Top 50 Innovators Shine with Clinical Advances and Galien Award Nomination
SIGNET
Innovative Targeted Cancer Drug Developer
Akeso
Innovative Antibody Drug Developer
Top 50 Selection Registration Method
Registration Official Website:www.biotech-top50.com
Registration Deadline:August 28, 2025
Contact:Ms. Yang 15521200167
1
"Medical Nobel Prize" Galien Award Nominates Signet Therapeutics, the Only Chinese Biopharmaceutical Company to Be Nominated
2
First Patient Enrolled in Phase III Clinical Study of Cadonilimab Combination Therapy for Perioperative Treatment of Gastric Cancer
PART.1
SIGNET
One of the highest honors in the international biopharmaceutical industry — the 2025 Prix Galien USA Award — recently announced its list of nominees,The 50 Rising Enterprises of the 6th Biotech Innovation – SIGNETSignet Therapeutics, with the world's first targeted drug for diffuse gastric cancer, SIGX1094R, has become the only Chinese biopharmaceutical company nominated for the "Best Biotechnology Product Award."。
SIGNET is a pioneer in the global "organoid + AI"-powered innovative targeted drug R&D model, and is a national high-tech enterprise as well as a specialized and innovative enterprise. The company currently has four first-in-class drug pipelines and one organoid platform under development. Its core pipeline, SIGX1094R, is the world's first targeted drug for diffuse gastric cancer, which has received IND approval from both the U.S. FDA and China's NMPA. It has also been granted Orphan Drug Designation (ODD) and Fast Track Designation (FTD) by the U.S. FDA. Currently, it is undergoing Phase I clinical trials at Peking University Cancer Hospital. This pipeline is also the world’s first drug to be advanced into clinical stages through an "organoid + AI" technology platform and is expected to enter Phase II clinical trials by the end of 2025.
PART.2
Akeso
Recently,Top 50 Biotech Innovation Enterprises of the First Session——Akeso (9926.HK) independently developed the world's first PD-1/CTLA-4 bispecific antibody new drug Cadonilimab (trade name: Kaitanni®) in combination with chemotherapy,The pivotal Phase III study (AK104-310/COMPASSION-33) for perioperative treatment of resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma has completed the first patient enrollment and dosing.The COMPASSION-33 study is the third pivotal Phase III trial of Cadonilimab in the field of gastric cancer, which is expected to significantly increase the radical resection rate for advanced gastric cancer patients, reduce the risk of tumor recurrence and metastasis, thereby improving the overall prognosis of patients. The indication will also help Cadonilimab achieve full coverage from unresectable advanced gastric cancer to resectable advanced gastric cancer treatment.
Akeso (9926.HK) is a leading company that integrates the research, development, production, and commercialization of globally pioneering or best-in-class innovative biopharmaceuticals. Since its establishment in 2012, the company has always been patient-centered and clinically value-oriented, creating a unique end-to-end Akeso comprehensive new drug R&D platform. It has built an innovative R&D system centered on Tetrabody bispecific antibody technology, Antibody-Drug Conjugate (ADC) technology, mRNA technology, and cell therapy technology, along with a GMP production system meeting international standards and an advanced commercial operation model. As a result, it has become a competitive biopharmaceutical innovation company on a global scale.
About the Top 50 Biotech Innovation Selection
The "Top 50 Biotech Innovation Enterprises in the Guangdong-Hong Kong-Macao Greater Bay Area" selection, hosted by the Zhongchuang Industry Research Institute and organized by the Guangdong Medical Valley, has been successfully held for seven consecutive years. As the largest and most dynamic multilateral resource exchange and sharing industrial innovation ecosystem in the Greater Bay Area's biopharmaceuticals industry, it aims to discover China's future biotech unicorns. The platform provides biotech enterprises with a comprehensive industrial hub for connecting businesses, academia, government, and other resources, accelerating the development of China’s biopharmaceuticals industry through industrial collaboration and resource aggregation.
For industry communication groups, cooperation, contributions, etc.
Please scan the QR code to add.
